The company has been in the news recently. One of the reasons is that it is going to release the cohort 3 clinical trial results soon. As mentioned by an analyst on SA, good results in the trial could be a strong catalyst for the stock. It could increase investor confidence in the company. Analysts have expressed positive opinion about the future prospects of Senesco, especially in light of its main drug candidate SNS01T. Investments by Chairman Harlan Waksal and Director Christopher Forbes at $26 equivalent in 2012 indicates their faith in company's future. Waksal has a successful track record as a biotech investor, and his investment in Senesco shows that he sees a lot of potential in SNS01T. Waksal co-founded Imclone which he ultimately sold to Eli Lilly (LLY) for $6.8 billion. SNS01T has a unique mechanism of action, and has the ability to modulate Factor 5A, a gene that regulates programmed cell death. The preclinical trial results were encouraging, and results of cohort 1 & 2 (low dosage) in multiple-myeloma patients were good. If the cohort 3 (higher dosage) results show higher efficacy and safety, then there is likely to be a major positive change in the investor outlook towards the company. The drug candidate also has use in inflammation, ischemia, and also in agriculture. The company owns numerous related patents, with applications in agriculture (increasing crop yield), programming of cell death etc. The risks of investments in development stage companies are high, though the rewards are also likely to be proportionate. The company will require funding from time to time to support the trials. Obtaining funds will squarely depend on the progress of the trials. Even if all goes well, FDA approval may take a few years. Competition in cancer field is huge, with most pharmaceutical giants having a strong presence. However, the size of the market does present a huge opportunity for the company.
